The Reassuring Testosterone Data Was Never Collected on a Prostate Like His
Newer evidence has quieted the old fear that testosterone worsens urinary symptoms. That evidence was gathered in men whose LUTS were mild or already treated — not a man with a symptom score of 22 who has never been treated at all.
G.V., 63, has coached his grandson's youth baseball team for the past four seasons and has recently found himself sitting out more of practice than he used to, citing fatigue that started gradually over the past year and has become hard to ignore. Two morning testosterone levels, drawn a month apart, both came back low, consistent with hypogonadism, alongside low libido and a noticeable loss of muscle mass he attributes to more than just aging. He wants to start testosterone therapy and has been reading about it for weeks.
What he has not addressed, in the same window of time, is his urinary symptoms. His AUA symptom score is 22 — past the 19 above which TRAVERSE, the trial doing most of the reassuring about testosterone and the prostate, excluded men outright — and he has been putting off dealing with it for over two years because "the other stuff seemed like the bigger problem." His post-void residual is elevated at 130mL, and he has never been started on any BPH medication. He has no history of urinary retention, no hematuria, and no other significant medical conditions. His residual, at better than twice the roughly 50mL usually treated as normal, is a marker most clinicians would flag on its own even before layering the testosterone question on top of it — and it has sat there, unaddressed, for as long as his hypogonadal symptoms have been building. He is, by his own account, mainly here about his energy and his libido, and somewhat surprised that his prostate has become part of the conversation at all. He is otherwise healthy — no diabetes, no cardiovascular disease — and has been an active, hands-on grandfather since retiring from construction work two years ago, which is part of why the fatigue has bothered him enough to finally bring it up.
His two testosterone levels — drawn a month apart specifically to avoid acting on a single, possibly spurious value — were 210 and 195ng/dL, both clearly below the threshold used to confirm biochemical hypogonadism. Set against that clean, well-documented hormonal picture, his urinary numbers look almost neglected by comparison: nobody has ever calculated his AUA score before today, and the 130mL residual was found only because it was checked as part of today's workup, not because anyone had been tracking it.
Whose data actually covers a man like him
The newer trials that reassured everyone about testosterone and LUTS — including the urinary safety data from TRAVERSE — studied men with mild-to-moderate or already-treated symptoms. He's at a symptom score of 22, untreated, with an elevated residual. That's not the population those studies covered, and extending their reassurance to him extrapolates past what's actually been shown.
I'd weigh that against the mechanism itself. The proposed harm — androgen-driven prostate growth precipitating retention — operates the same way in every patient regardless of his baseline symptom severity. If the newer data found no meaningful signal even in that mechanistic pathway, the population gap is a real limitation, but it isn't strong grounds on its own to withhold real quality-of-life benefit from a man who is genuinely symptomatic.
A consistent mechanism across severity levels is a reasonable argument, but it doesn't substitute for having actually studied men at his severity — which nobody has.
You're both arguing about whether to extrapolate data that was never built for him. His BPH has been neglected for two years regardless of the testosterone question — treat that first. Once his symptom score and residual come down on adequate therapy, he's no longer the untreated-severe-LUTS population the newer literature doesn't cover, and starting testosterone at that point applies the reassuring data to a patient it actually describes. Sequencing solves this without either of you having to be wrong.
Agreed: start combination BPH therapy now, defer testosterone initiation, and reassess his AUA symptom score, post-void residual, and hypogonadal symptoms together in three to four months once BPH therapy has had time to act.
Not agreed: whether a partial LUTS improvement — say a symptom score dropping to 14, still moderate — should be enough to proceed with testosterone at reassessment, or whether the team should hold out for a more complete response first. The endocrinologist would proceed at any meaningful improvement; the urologist wants to be closer to full resolution before crossing into testosterone territory.